TScan Therapeutics (TCRX) director awarded 67,000 stock options at $0.9946

Rhea-AI Filing Summary

TScan Therapeutics director Garry A. Nicholson received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036. They vest in full on the earlier of May 20, 2027 or the next annual stockholder meeting, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nicholson Garry A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	67,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 67,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 67,000 options Exercise price: $0.9946 per share Underlying shares: 67,000 shares +2 more

5 metrics

Option grant size 67,000 options Stock Option (Right to Buy) granted to director on May 20, 2026

Exercise price $0.9946 per share Exercise price for the granted stock options

Underlying shares 67,000 shares Voting Common Stock underlying the stock options

Expiration date May 20, 2036 Expiration of Garry Nicholson’s stock options

Post-transaction derivative holdings 67,000 options Total derivative securities held following the grant

Key Terms

Stock Option (Right to Buy), exercise price, Voting Common Stock, vest and become exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 0.9946"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Voting Common Stock financial

"underlying_security_title: Voting Common Stock"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable in full"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicholson Garry A

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9946	05/20/2026		A		67,000		(1)	05/20/2036	Voting Common Stock	67,000	$0.00	67,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Zoran Zdraveski, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TScan Therapeutics (TCRX) report for Garry Nicholson?

TScan Therapeutics reported a stock option grant to director Garry A. Nicholson. He received options for 67,000 shares of Voting Common Stock as compensation, rather than buying shares in the open market, reflecting a routine equity award for board service.

What is the exercise price of Garry Nicholson’s new TScan (TCRX) stock options?

The new stock options granted to Garry Nicholson have an exercise price of $0.9946 per share. This is the price he would pay to acquire each share if he chooses to exercise the options after they vest and before expiration.

When do Garry Nicholson’s TScan Therapeutics (TCRX) options vest?

The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual stockholder meeting. Vesting is conditional on Nicholson’s continued service with the company through that vesting date, according to the filing footnote.

When do the granted TScan (TCRX) stock options held by Garry Nicholson expire?

The granted stock options expire on May 20, 2036. After this expiration date, Garry Nicholson can no longer exercise these options to buy shares, even if they have vested and were otherwise exercisable before that time.

How many TScan (TCRX) derivative securities does Garry Nicholson hold after this Form 4 transaction?

Following this transaction, Garry Nicholson holds 67,000 derivative securities related to TScan, all from this option grant. The filing shows these options as directly owned and tied to Voting Common Stock as the underlying security.